Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.

Education

Biotechnology

Nuvalent

James Porter

Anna Protopapas

Philip Engel

Wenzhe Fan

Jeffrey Lee

Henry Pelish

Deb Miller

Alex Balcom

Christopher Turner

Darlene Noci

Jessie Lin

Kristi Byrnes

Matthew Metivier

Leadership Team

Nuvalent

Org chart

Teams

Leadership Team

Similar companies